Table 1.
Patient characteristics.
| Study cohort (n = 80) | |
|---|---|
| Male sex [n] | 61 (76) |
| Age [years] | 57 (50–64) |
| Aetiology of cirrhosis | |
| Alcoholic [n] | 63 (79) |
| Viral [n] | 5 (4) |
| NASH [n] | 1 (1) |
| Others [n] | 11 (14) |
| Active alcohol consumption yes/no/unknown | 40/35/5 |
| Alcoholic hepatitis [n] | 9 (11.3) |
| Child-Pugh-Stage: A/B/C | 0/29/51 |
| Child-Pugh-Score | 10 (9–12) |
| MELD | 17 (11–23) |
| SOFA-CLIF | 7 (4–9) |
| ACLF: 0/I°/II°/III° | 56/14/5/5 |
| Infections [n] | |
| SBP [n] | 12 (15) |
| Infection other than SBP [n] | 32 (40) |
| Upper gastrointestinal bleeding [n] (%) | 10 (12.5) |
| Mean arterial pressure [mmHg] | 87 (74–100) |
| Diabetes mellitus [n] | 10 (12.5) |
| Insulin therapy [n] | 6 (7.5) |
| Leukocyte count [/nl] | 7.1 (5.0–11.7) |
| Thrombocyte count [/nl] | 142 (96–189) |
| C-reactive protein [mg/l] | 29.9 (13.3–60.9) |
| Creatinine [µmol/l] | 85.5 (63.3–148.0) |
| Bilirubin [mg/dl] | 2.08 (0.99–5.15) |
| Albumin [g/l] | 24 (20–31) |
| INR [AU] | 1.5 (1.2–1.9) |
| ALT [µmol/(l × s)] | 0.56 (0.37–1.05) |
Continuous data are given as median and interquartiles; nominal data [n] are given as n and percentage of total number study patients. Abbreviations: ACLF, acute-on-chronic liver failure; ALT, alanine aminotransferase; INR, international normalized ratio; MELD, model of end stage liver disease; NASH, non-alcoholic steatohepatitis; SBP, spontaneous bacterial peritonitis; SOFA-CLIF, sequential organ failure assessment in chronic liver failure.